TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care
Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platel...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-10-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2019.1704713 |
| _version_ | 1797684215926489088 |
|---|---|
| author | Joao D. Dias Carlos G Lopez-Espina Kevin Bliden Paul Gurbel Jan Hartmann Hardean E Achneck |
| author_facet | Joao D. Dias Carlos G Lopez-Espina Kevin Bliden Paul Gurbel Jan Hartmann Hardean E Achneck |
| author_sort | Joao D. Dias |
| collection | DOAJ |
| description | Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platelet counts were prepared from healthy volunteers. Platelet function was adjusted using seven concentrations of abciximab and evaluated by light transmission aggregometry (LTA) with TRAP agonist. Maximum amplitude (MA), reaction time (R) and activated clotting time (ACT) were assessed in citrated kaolin (CK), CK with heparinase (CKH), citrated RapidTEG® (CRT), and citrated functional fibrinogen (CFF) assays. Positive correlations were observed between platelet count and CK.MA, CKH.MA, and CRT.MA (p < .0001), and CK.R, CKH.R, and CRT.ACT (p < .05). Platelet count could be accurately quantified in the range 28–91 k/μL, 28–86 k/μL and 28–74 k/μL for CK.MA, CKH.MA, and CRT.MA, respectively. CK.MA, CKH.MA, and CRT.MA showed significant negative relationships with abciximab concentration (p < .001). Platelet function inhibition was detected by all three assays at >68% measured by LTA and quantified in the range 68.4–82% (CK), 69.4–88% (CKH), and 69.7–76% (CRT). This demonstrates the TEG®6s analyzer can accurately evaluate platelet count and function at the site-of-care. |
| first_indexed | 2024-03-12T00:26:26Z |
| format | Article |
| id | doaj.art-a642748ce8cc4e0d9e9d2140cf5ff48d |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:26:26Z |
| publishDate | 2020-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-a642748ce8cc4e0d9e9d2140cf5ff48d2023-09-15T10:32:02ZengTaylor & Francis GroupPlatelets0953-71041369-16352020-10-0131793293810.1080/09537104.2019.17047131704713TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-careJoao D. Dias0Carlos G Lopez-Espina1Kevin Bliden2Paul Gurbel3Jan Hartmann4Hardean E Achneck5Haemonetics CorporationHaemonetics CorporationSinai Center for Thrombosis Research Sinai Hospital, 2401 W. Belvedere Ave, Baltimore MD 21215Sinai Center for Thrombosis Research Sinai Hospital, 2401 W. Belvedere Ave, Baltimore MD 21215Haemonetics CorporationHaemonetics CorporationKnowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platelet counts were prepared from healthy volunteers. Platelet function was adjusted using seven concentrations of abciximab and evaluated by light transmission aggregometry (LTA) with TRAP agonist. Maximum amplitude (MA), reaction time (R) and activated clotting time (ACT) were assessed in citrated kaolin (CK), CK with heparinase (CKH), citrated RapidTEG® (CRT), and citrated functional fibrinogen (CFF) assays. Positive correlations were observed between platelet count and CK.MA, CKH.MA, and CRT.MA (p < .0001), and CK.R, CKH.R, and CRT.ACT (p < .05). Platelet count could be accurately quantified in the range 28–91 k/μL, 28–86 k/μL and 28–74 k/μL for CK.MA, CKH.MA, and CRT.MA, respectively. CK.MA, CKH.MA, and CRT.MA showed significant negative relationships with abciximab concentration (p < .001). Platelet function inhibition was detected by all three assays at >68% measured by LTA and quantified in the range 68.4–82% (CK), 69.4–88% (CKH), and 69.7–76% (CRT). This demonstrates the TEG®6s analyzer can accurately evaluate platelet count and function at the site-of-care.http://dx.doi.org/10.1080/09537104.2019.1704713bleeding managementplatelet countplatelet functionpoint-of-carethromboelastography |
| spellingShingle | Joao D. Dias Carlos G Lopez-Espina Kevin Bliden Paul Gurbel Jan Hartmann Hardean E Achneck TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care Platelets bleeding management platelet count platelet function point-of-care thromboelastography |
| title | TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care |
| title_full | TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care |
| title_fullStr | TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care |
| title_full_unstemmed | TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care |
| title_short | TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care |
| title_sort | teg r 6s system measures the contributions of both platelet count and platelet function to clot formation at the site of care |
| topic | bleeding management platelet count platelet function point-of-care thromboelastography |
| url | http://dx.doi.org/10.1080/09537104.2019.1704713 |
| work_keys_str_mv | AT joaoddias teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare AT carlosglopezespina teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare AT kevinbliden teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare AT paulgurbel teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare AT janhartmann teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare AT hardeaneachneck teg6ssystemmeasuresthecontributionsofbothplateletcountandplateletfunctiontoclotformationatthesiteofcare |